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Helicobacter pylori infection is one of the most common infectious diseases worldwide. Although 
the prevalence of H. pylori is gradually decreasing, approximately half of the world's population 
still becomes infected with this disease. H. pylori is responsible for substantial gastrointestinal 
morbidity worldwide, with a high disease burden. It is the most common cause of gastric and 
duodenal ulcers and gastric cancer. Since the revision of the H. pylori clinical practice guidelines 
in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a 
clarithromycin-based triple therapy for 7 days. According to a nationwide randomized controlled 
study conducted by the Korean College of Helicobacter and Upper Gastrointestinal Research 
released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due 
to increased antimicrobial resistance, especially from clarithromycin. The clinical practice guide-
lines for the treatment of H. pylori were updated according to evidence-based medicine from a 
meta-analysis conducted on a target group receiving the latest level of eradication therapy. The 
draft recommendations developed based on the meta-analysis were finalized after an expert 
consensus on three recommendations regarding the indication for treatment and eight recom-
mendations for the treatment itself. These guidelines were designed to provide clinical evidence 
for the treatment (including primary care treatment) of H. pylori infection to patients, nurses, 
medical school students, policymakers, and clinicians. These may differ from current medical 
insurance standards and will be revised if more evidence emerges in the future. (Gut Liver 
2021;15:168-195)
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INTRODUCTION
1. Background
Helicobacter pylori infection is the most common cause 
of infectious disease in the world. Its prevalence varies 
worldwide, e.g., 11% in Northern Europe, 23.1% in Cana-
da, and 30.0% in the United States, but compared to 72% 
to 80% in South America and 91% in Nigeria.1 The preva-
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lence is 50% higher in Korea.2 H. pylori causes progressive 
injury to the gastric mucosa and play an important role 
in gastrointestinal diseases such as asymptomatic chronic 
gastritis, peptic ulcer disease, atrophic gastritis, intestinal 
metaplasia (IM), gastric mucosa-associated lymphoid tis-
sue lymphoma and gastric adenocarcinoma.3,4
Many epidemiologic studies have shown the relation-
ship between H. pylori and gastric cancer. The Asia-Pacific 
region (China, Japan, and Korea) which has a high risk of 
gastric cancer shows a high prevalence of H. pylori infec-
tion. In 2017, the standardized incidence of gastric cancer 
in Korea was 32.0 per 100,000 person, which was a leading 
cause of cancer second to thyroid cancer.4,5 Considering 
the high prevalence and high fatality in advanced cases of 
gastric cancer, finding effective measures for primary or 
secondary prevention of gastric cancer is a public health 
priority. In 2013, the Japanese health insurance has begun 
covering eradication therapy for H. pylori-positive gastri-
tis, even though there is no concrete evidence on the eradi-
cation therapy for H. pylori gastritis.6,7 However, it is not 
clear whether there is a definite benefit compared to the 
harms due to their high cost and potential increase in anti-
biotic resistance with mass eradication therapy to H. pylori 
infection. In 2013, clinical practice guidelines for diagnosis 
and treatment of H. pylori infection were developed to ad-
dress domestic situations with an adaptation process.8 
The present revision of previous guidelines intended to 
generate evidence by conducting a systematic review of the 
additive indication such as eradication therapy of H. pylori 
in patients with unexplained iron deficiency anemia (IDA), 
post-endoscopic resection (ER) of gastric adenoma and 
atrophy gastritis and/or IM.
For effective eradication, multi-antibiotics regimens 
with anti-secretory agents are used. Unsuccessful eradica-
tion is associated with high bacterial load, high gastric 
acidity, the virulence of Helicobacter strains and poor 
compliance. However, growing antibiotics resistance, par-
ticularly clarithromycin resistance seems to be the major 
cause of decreasing eradication rate.9 
In the last 20 years, a widespread use of antibiotics, such 
as clarithromycin for respiratory symptoms and levofloxa-
cin for urinary infection, has increased the primary H. 
pylori resistance in many countries.10 Systematic review 
revealed that the overall H. pylori antibiotic resistance rates 
were 17.2% (95% confidence interval [CI], 16.5% to 17.9%) 
for clarithromycin, 26.7% (95% CI, 25.2% to 28.1%) for 
metronidazole, and 11.2% (95% CI, 9.6% to 12.7%) for 
amoxicillin.10 Based on these changes, European guidelines 
recommended to extend the standard triple therapy to 14 
days where clarithromycin resistance was >15%–20%.11 In 
Korea, the clarithromycin resistance rates rose from 9% in 
1995 and 13.8% in 2003 to 16.7% in 2005, and 17.8% in a 
nationwide study in 2018.2,12-14
With dynamic changes of the epidemiology of H. py-
lori and increasing issue of antibiotics resistance, a new 
approach is needed for effective management. In these 
updated guidelines, we aimed to present the appropriate 
H. pylori treatment for Korea by conducting systematic re-
view and meta-analysis to identify the clinical evidence for 
alternative treatments to the standard 7-day triple therapy.
METHODS
1. Revision process 
1) Guidelines development organization
The Steering Committee which consisted of the Presi-
dent and the executive members of the Korean College of 
Helicobacter and Upper Gastrointestinal Research estab-
lished development strategies, appointed working group 
members, and approved budgets related to the project. 
This guideline included multidisciplinary processes by 
the Korean Society of Clinical Microbiology, the Korean 
Society of Pathologists, and the Korean Society of Gastro-
enterology. To establish the methodology for developing 
guidelines, two methodological experts (Miyoung Choi 
and Ein Soon Shin) and Professor Soo Young Kim, a mem-
ber of the Korean Medical Association’s Clinical Treatment 
Guidelines Development Committee, conducted four 
workshops on the literature search, quality assessment, 
meta-analysis, and methods of expert consensus.
In the course of developing or approving the guidelines, 
the members of the working group were asked to confirm 
that they had no conflict of interest by accepting advice or 
employment from commercially relevant organizations, 
commercial ownership interests, research funds, and case 
fees, or intellectual property rights (e.g., patents, trade-
marks, licensing or royalties) for drugs related to the devel-
opment of the guidelines, and whether their families had 
the same relationship as those described above. 
2) Patient’s preference and perspective
A web survey using structured questionnaires was 
administered to the largest Internet community associ-
ated with gastrointestinal diseases was to identify the 
experiences, expectations and preferences of patients in 
this guideline. A total of 233 subjects responded, 64.4% 
of whom were adult women and 57.5% of whom were H. 
pylori-positive. Among those who were positive for H. py-
lori, 86.7% wanted treatment, the reasons for which were 
for prevention of stomach cancer (44.6%), improvement of 
stomach symptoms (28.8%), and fear of transmitting infec-
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tion to others (9.9%). The most worrisome aspect of the H. 
pylori treatment was 80.3% of the drug’s adverse reactions. 
Based on these points, the topic of adverse effect of eradi-
cation therapy and the impact of H. pylori eradication on 
gastric adenoma after ER of neoplastic lesions in the stom-
ach, atrophic gastritis and IM, and the precursor to gastric 
cancer were added as key questions. 
3) Guideline development process
The scope of clinical practice guidelines was determined 
by deriving key questions tailored to the PICO (population-
intervention-comparison-outcome) format using nominal 
group techniques in working group.15 De novo method 
was implemented in this revision because the guidelines 
required the latest evidence as the dynamics of the H. pylori 
infection and related gastrointestinal diseases in Korea are 
changing rapidly.
(1) Systematic review and meta-analysis 
A systematic review was conducted at each PICO. Dr. 
Miyoung Choi of the National Evidence-based Healthcare 
Collaborating Agency and a working group member of 
each subject selected appropriate search key words and 
conducted a literature search from July to August 2018 
using the Ovid-MEDLINE, EMBASE, Cochrane Library, 
KoreaMed and KMBASE databases; the key words were 
listed in the appendix. The common inclusion criteria for 
the studies were as follows: (1) adult subjects or patients 
as the study population, (2) written in English or Korean, 
(3) systematic reviews and meta-analyses, randomized or 
non-randomized trials, and observational studies, (4) pub-
lished between 2008 and 2018, and (5) studies with proper 
results reported. The common exclusion criteria were as 
follows: (1) studies on children or teenagers, (2) studies 
with no proper results reported, (3) duplicated publica-
tion, (4) impossible to obtain original text, and (5) expert 
opinion, case series or report, narrative review, or guide-
lines. Two independent members reviewed the literatures 
and selected the final studies according to the inclusion 
and exclusion criteria. The literature selection process was 
summarized in the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) plot for each 
PICO. An example of the process of literature selection 
for key question 1 is shown in Fig. 1. The quality of finally 
selected studies was assessed using quality assessment tools 
according to the study design. Randomized controlled tri-
als (RCTs) were evaluated using the Cochrane Risk of Bias 
(RoB) tool,16 while non-randomized clinical studies were 
assessed using the Risk of Bias Assessment Tool for Non-




































Records excluded according to selection
criteria (n=5)
1. Patients not interested in the key question (n=0)
2. No intervention related to key question (n=0)
3. No comparative intervention related to key
question (n=2)
4. When appropriate results are not reported (n=1)
5. Non English or Korean (n=0)
6. When original text cannot be obtained (n=2)
7. Non-human study (n=0)
Records after duplicates removed (n=241)
Records screened (n=241)
Full-text articles assessed for eligibility (n=8)
Studies included for synthesis (n=3)
Records excluded by title and abstract
screening (n=233)
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flowchart showing the selection process for key question 1.
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not consistent as the two paired working members, the two 
members and the chairman coordinated a final evaluation.
(2) Elicitation of recommendations: level of evidence and 
grade of recommendation
After systematic literature review, the evidence table 
was organized and meta-analysis was conducted. Evidence 
profiles were created based on “Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE)” 
(Table 1).18 GRADEpro software was used to rank the quali-
ty of evidence according to four categories: high, moderate, 
low, and very low. The quality assessment of the evidence 
was then used to determine the strength of the supporting 
evidence that informs a recommendation (Table 2).19
A literature search was conducted to utilize resources 
and economic evaluation. The cost of H. pylori eradica-
tion, which uses antibiotics and proton pump inhibitors 
(PPIs) for 7–14 days, was not significantly different be-
tween the treatment methods. The tailored therapy based 
on H. pylori susceptibility to antibiotics may be cost-effec-
tive in a high clarithromycin-resistant region compared to 
standard empirical triple therapy. There are reports that 
tailored treatment is superior in terms of cost-effectiveness 
if the eradication rate of H. pylori is lowered below 75.3%. 
Therefore, the tailored treatment based on H. pylori sus-
ceptibility to antibiotics was added to the recommenda-
tion.20,21
(3) Expert consensus with modified Delphi agreement 
process 
The aim of expert consensus by modified Delphi meth-
ods was to determine the extent to which experts agreed 
about draft recommendation including evidence.22 The 
first round of Delphi process was conducted with E-mail 
voting and 44 experts were invited, with 30 participating 
in the first agreement. The first round was investigated us-
ing the 9-Likert scale self-reporting questionnaire asking 
the extent of agreement, along with evidence data from the 
Development Committee for each recommendation. In 
the response scale, one point was “completely disagreeable” 
and nine points were “very agreeable.” Consent was consid-
ered when the ratio of points from 7 to 9 (high agreement) 
was more than two-thirds without complete disagreement. 
Eight recommendations were agreed upon for a total of 
12 recommendations. Indication of H. pylori eradication 
therapy with IDA and atrophy gastritis/IM and eradica-
tion regimen of H. pylori with standard triple therapy and 
sequential therapy failed to reach agreement, so the Devel-
opment Committee revised these four recommendations 
after the first voting and conducted the second round of 
voting in a face-to-face agreement (December 14, 2019). A 
second round of voting was conducted anonymously, and 
recommendations for atrophy gastritis/IM were rejected 
by 48% of 23 respondents, with the remaining recom-
mendations passed and finally 11 recommendations were 
adopted.
(4) Internal and external review 
In the second round of face-to-face voting for the expert 
consensus process, various drafts were adopted after the 
anonymous vote. After the process of expert agreement 
and external review, the draft was revised with their opin-
ions.
Table 1. Level of Evidence and Strength of Recommendation
Explanation
Class
    High At least one RCT or SR/meta-analysis with no concern of study quality 
    Moderate At least one RCT or SR/meta-analysis with minor concern of study quality or  
at least one cohort/case-control/diagnostic test design study with no concern of study quality 
    Low At least one cohort/case-control/diagnostic test study with minor concern of study quality or  
at least one single arm before-after study, cross-sectional study with no concern of study quality 
    Very low At least one cohort/case-control/diagnostic test design study with serious concern of study quality or  
at least one single arm before-after study, cross-sectional study with minor/severe concern of study quality
Grade classification
    Strong for The benefit of intervention is greater than harm with high or moderate level of evidence, which can be strongly recom-
mended in most clinical practice.
    Weak for The benefit and harm of intervention may vary depending on the clinical situation or patient/social value. It is recom-
mended conditionally according to the clinical situation.
    Against The benefit and harm of intervention may vary depending on the clinical situation or patient/social value. Intervention 
may not be recommended in clinical practice.
    No recommendation It is not possible to determine the recommendation direction owing to a lack of evidence or discrepancy of result. Thus 
further evidence is needed.
RCT, randomized controlled trial; SR, systematic review.
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(5) Dissemination of the guidelines and update information
This guideline was provided on the Korean College of 
Helicobacter and Upper Gastrointestinal Research (http://
www.hpylori.or.kr) and the Korean Association of Internal 
Medicine (http://www.kaim.or.kr) websites. In addition, 
this guideline will be published in Korean and English as a 
paper and will be spread throughout the academic sympo-
sium.
CLINICAL PRACTICE GUIDELINE
1. Newly added indication for H. pylori eradication 
1) Iron deficiency anemia
Can H. pylori eradication increase the hemoglobin in 
patients with idiopathic IDA?
Statement 1. H. pylori eradication can be helpful to 
improve the anemia in subset of adults with unex-
plained IDA.
Grade of recommendation: weak
Level of evidence: very low
Experts’ opinions: completely agree (28.0%), mostly 
agree (48.0%), partially agree (10.0%), mostly disagree 
(10.0%), completely disagree (5.0%), not sure (0%)
Anemia is a major health problem and mostly caused by 
iron deficiency.23,24 The estimated prevalence of anemia is 
24.8% (95% CI, 22.9% to 26.7%), affecting 1.62 billion peo-
ple (95% CI, 1.50 to 1.74 billion) globally,23 and concentrat-
ed in preschool children and women. H. pylori infection 
causes diverse gastrointestinal diseases, including chronic 
gastritis, peptic ulcer disease and cancer. Furthermore, H. 
pylori chronic gastritis can induce decreasing gastric acid 
secretion and gastric ascorbic acid, which are essential for 
the absorption of dietary iron.25,26
H. pylori has been associated with IDA. A recent meta-
analysis revealed a significantly higher likelihood of IDA in 
subjects with H. pylori infection (pooled odds ratio [OR], 
1.72; 95% CI, 1.23 to 2.42).27 However, this association was 
strong in children, but subgroup analysis of adult popula-
tion revealed weaker association with significant heteroge-
neity (pooled OR, 1.70; 95% CI, 1.01 to 2.85).23 
The role of H. pylori infection in IDA was shown in 






Indications   1. H. pylori eradication can be helpful to improve the anemia in subset of adults with 
unexplained iron deficiency anemia.
Very low Weak
  2. H. pylori eradication can be recommended after endoscopic resection for H. pylori-
positive gastric adenoma to prevent metachronous recurrence.
Low Weak
  3. H. pylori eradication can be recommended for long-term improvement of dyspeptic 
symptoms in patients with functional dyspepsia.
High Weak
First-line therapy   4. Standard triple therapy (standard dose PPI, amoxicillin 1 g, and clarithromycin 500 mg 
twice daily) for 14 days is recommended for first-line regimen.
Moderate Strong
  5. Sequential therapy (standard dose PPI, amoxicillin 1 g twice daily for 5 days followed 
by standard dose PPI, clarithromycin 500 mg, and metronidazole 500 mg twice daily 
for 5 days) can be one of first-line therapies for H. pylori eradication.
High Strong
  6. Concomitant therapy (standard dose PPI, clarithromycin 500 mg, amoxicillin 1 g, and 
metronidazole 500 mg twice daily for 10 days) is recommended as a first-line treat-
ment.
High Strong
  7. Clarithromycin resistance test by PCR or sequencing is recommended when a 7-day 
standard triple therapy is considered as a first-line treatment.
Low Strong
  8. Eradication rates of bismuth quadruple therapy (standard dose PPI twice daily, met-
ronidazole 500 mg three times daily, bismuth 120 mg and tetracycline 500 mg four 
times daily for 10 to 14 days) are similar to 14 days standard triple therapy, 10 days 
concomitant therapy, and 10 days sequential therapy. However, because of its high 
adverse effects and potential use as second-line therapy, it can be recommended to 
be used as first-line therapy if other first-line therapy options are not available.
Moderate Weak
Salvage therapy   9. After failure of standard triple therapy, a bismuths quadruple therapy (PPI, bismuth, 
tetracycline, and metronidazole) for 14 days is recommended as a second-line therapy.
High Strong
10. After failure of non-bismuth quadruple therapy (sequential or concomitant therapy), a 
bismuth quadruple therapy is recommended as a second-line therapy.
Very low Strong
11. After failure of bismuth quadruple therapy as 1st-line or 2nd-line therapy (after failed 
standard triple or non-bismuth quadruple therapy), a levofloxacin triple therapy is 
suggested as a salvage therapy.
Very low Weak
PPI, proton pump inhibitor; PCR, polymerase chain reaction.
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studies with H. pylori eradication therapy combined with 
iron supplementation to treat the IDA. However, these 
studies were heterogeneous because of confounders in-
cluding age (children or adolescents vs adults), sex and 
different study setting in terms of different definition of 
IDA or outcomes (quantitative assessment of ferritin or he-
moglobin or qualitative assessment, such as recovery from 
anemia). Meta-analysis including children, adolescents, 
or adults showed significant increase of ferritin after the 
eradication, not hemoglobin. Meta-analysis of seven RCTs 
showed increased ferritin, standardized mean difference 
of 0.53 (95% CI, 0.21 to 0.85), but not hemoglobin, stan-
dardized mean difference of 0.36 (95% CI, –0.07 to 0.78).27 
However, there were limited studies which showed the 
efficacy of H. pylori eradication in adult population. Non-
randomized comparative study in adults with IDA showed 
the additional effect of H. pylori eradication on iron sup-
plement in adult patients with IDA and H. pylori-positive 
chronic gastritis.28 In a prospective observational study, 
H. pylori infection was correlated with low serum ferritin 
level and after eradication, serum ferritin increased; how-
ever, the sample size was too small.29 In this study, serum 
ferritin in premenopausal women was significantly lower 
than that of postmenopausal women, but not different in 
men. In other observational studies with adult patients 
with IDA, IDA was resolved after 38.1% of eradication of H. 
pylori-eradicated patients (32/84). This was more frequent 
in men and postmenopausal women compared with pre-
menopausal women (75% vs 23%, p<0.01).30 Despite the 
very low level of evidence, it was decided as a “weak rec-
ommendation” because short-term treatment of H. pylori 
infection has the potential for long-term benefits and low 
risk for serious harm.
2) After ER of gastric adenoma
Is H. pylori eradication helpful to prevent metachro-
nous recurrence after ER of gastric adenoma?
Statement 2. H. pylori  eradication can be recom-
mended after ER for H. pylori-positive gastric adenoma 
to prevent metachronous recurrence.
Grade of recommendation: weak
Level of evidence: low
Experts’ opinions: completely agree (60.0%), mostly 
agree (20.0%), partially agree (20.0%), mostly disagree 
(0%), completely disagree (0%), not sure (0%)
Many studies have reported that the incidence rate of 
metachronous cancer decreased with H. pylori eradication 
after ER of early gastric cancer (EGC).31-33 Thus, H. pylori 
should be eradicated to prevent metachronous recurrence 
after ER of EGC. However, there was no definite guideline 
about H. pylori eradication after ER of gastric adenoma. 
Until now, there were two RCTs about H. pylori eradica-
tion to prevent metachronous gastric cancer after ER of 
gastric tumors including EGC and adenoma (Supplementa-
ry Table 1).31-33 Three retrospective studies about H. pylori 
eradication after ER of gastric adenoma were reported.34-36 
All of them were conducted in Korea. According to studies, 
the incidence of metachronous recurrence was lower in H. 
pylori-eradicated group than non-eradicated group (3.24% 
vs 4.87%33; 7.69% vs 14.29%31; 7.76% vs 10.80%34; 8.20% 
vs 19.44%35; 4.71% vs 11.36%36). When meta-analysis in-
cluded five studies, the effect of H. pylori on prevention of 
metachronous recurrence after ER of gastric adenoma was 
statistically significant (OR, 0.55; 95% CI, 0.34 to 0.92) (Fig. 
2).
According to studies, H. pylori eradication is helpful to 
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M-H, fixed, 95% CI
Odds ratio
Fig. 2. Comparison of the occurrence of metachronous gastric cancer after endoscopic resection of gastric adenoma between Helicobacter pylori 
(Hp) eradication and placebo treatment.
M-H, Mantel-Haenszel test; CI, confidence interval.
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enoma. Therefore, H. pylori eradication is indicated after 
ER for H. pylori-positive gastric adenoma. However, RCT 
focused on gastric adenoma is required to support this rec-
ommendation.
3) Functional dyspepsia
Is H. pylori eradication helpful in symptom relief in pa-
tients with functional dyspepsia?
Statement 3. H. pylori eradication can be recommend-
ed for long-term improvement of dyspeptic symptoms 
in patients with functional dyspepsia. 
Grade of recommendation: weak
Level of evidence: high
Experts’ opinions: completely agree (43.3%), mostly 
agree (26.7%), partially agree (23.4%), mostly disagree 
(3.3%), completely disagree (3.3%), not sure (0%)
In the meta-analysis of RCTs, when H. pylori was eradi-
cated in dyspeptic patients, the symptom improvement 
was not significant in the short-term (3 months) follow-
up, but symptoms were significantly improved in the long-
term (6 to 12 months) follow-up.37,38 Based on these results, 
the Maastricht V guidelines in Europe and the U.S. and 
Canadian guidelines strongly recommend the eradication 
of H. pylori as the first-line treatment for dyspepsia.11,39
In the present guideline, 18 RCTs from January 1997 to 
December 2017 were selected and meta-analysis was con-
ducted to evaluate the long-term effects of H. pylori eradi-
cation in patients with dyspepsia (Supplementary Table 
2).40-57 In a meta-analysis of 4,672 patients from 18 RCTs, 
the risk ratio (RR) of persistence of dyspeptic symptoms 
in the control group was 1.18 (95% CI, 1.07 to 1.31) com-
pared with the eradication group. Although statistically 
significant, the number of patients needed for treatment 
(number needed to treat, NNT) was 14, and heterogeneity 
among studies was moderate (I2 =34%) (Supplementary 
Fig. 1).58 
Because of the heterogeneity among the studies, sub-
group analysis was performed by region to analyze five 
RCTs from the Asian regions and 13 RCTs from outside 
Asian regions. Meta-analysis from RCTs from outside 
Asia regions showed significant improvement of dyspeptic 
symptoms in eradication group (RR, 1.22; 95% CI, 1.08 to 
1.38; I2=33%). However, because of analysis of RCTs from 
Asia, the effect of eradication on improvement of dyspeptic 
symptoms was not significant (RR, 1.10; 95% CI, 0.92 to 
1.31; I2=32%). 
In summary, eradication of H. pylori improved dys-
peptic symptoms significantly, however, the clinical effect 
was not large due to the improvement of symptoms in 1 of 
14 treated patients (NNT=14) and the result of subgroup 
analysis of RCTs conducted in Asia was not statistically sig-
nificant. The prevalence of H. pylori in Korea is estimated 
to be 54% (95% CI, 50.1% to 57.8%) according to a study 
that estimates the prevalence of H. pylori worldwide.59 In 
areas with high prevalence of H. pylori, costs, adverse ef-
fects associated with eradication therapy, the risk of emer-
gence of resistance strains, and re-infection are thought to 
be higher than those of low prevalence regions. Therefore, 
in the present guideline, it was decided to make weak rec-
ommendations despite the high level of evidence for H. py-
lori eradication in patients with functional dyspepsia. The 
RCTs, including cost-effectiveness analysis of eradication 
therapy in patients with functional dyspepsia in areas with 
high prevalence of H. pylori, including in Korea, are likely 
to be needed.
4) Chronic atrophic gastritis and IM
Is H. pylori eradication effective to prevent gastric can-
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Fig. 3. Forest plot of studies reporting the impact of Helicobacter pylori eradication on gastric cancer from studies involving the general population.
M-H, Mantel-Haenszel test; CI, confidence interval.
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H. pylori eradication can reduce the risk of gastric can-
cer development. However, it is controversial whether the 
eradication can be beneficial in individuals with pre-neo-
plastic lesions including chronic atrophic gastritis (CAG) 
and IM. 
Recently published two meta-analyses showed that 
individuals with non-atrophic or CAG benefited from 
eradication in reducing the risk of gastric cancer, whereas 
individuals with IM and/or dysplasia did not.60,61 The effect 
of H. pylori eradication can be affected by the degree of 
mucosal atrophy. H. pylori eradication can be more benefi-
cial to subjects with mild mucosal atrophy than those with 
extensive atrophic gastritis.62 Maastricht V guideline rec-
ommended that the risk for gastric cancer can be reduced 
more effectively by eradicating H. pylori before atrophy 
and IM develop.11 
However, the two meta-analyses included the studies 
that evaluated the effect of H. pylori eradication on the oc-
currence of metachronous gastric cancers after ER of EGC, 
as well as the studies in the general population. The effect 
of H. pylori eradication may be different between in the 
general population and in the high-risk group. Moreover, 
a population-based cohort study in China, which was not 
included in the previous meta-analyses, showed that H. 
pylori eradication can benefit individuals with IM and/or 
dysplasia at baseline, suggesting H. pylori eradication can 
benefit an entire population regardless of the baseline gas-
tric histopathology.63 
When the meta-analysis was performed using the RCTs 
in the general population only, H. pylori eradication signif-
icantly reduced the incidence of gastric cancer, as in previ-
ous studies (Fig. 3). In a subgroup analysis that included 
only subjects with CAG or IM, eradication had no effect on 
the prevention of gastric cancer, and two studies involving 
subjects without CAG and IM did not demonstrate signifi-
cant gastric cancer prevention effect (Supplementary Fig. 
2). However, in the latter case, the number of incidences 
of gastric cancer were small, and there were limitations in 
drawing an accurate conclusion. In expert consensus based 
on these analyses, only 48.0% agreed in the first e-mail 
questionnaire, and only 63.3% agreed in the second face-
to-face meeting. In other words, there is no firm evidences 
or expert agreement to recommend eradication of H. py-
lori in subjects with CAG or IM, so re-discussion is needed 
after more researches have been accumulated. The indica-
tions for H. pylori eradication treatment presented above 
are summarized in Table 3.
2. H. pylori eradication therapy
1) First-line therapy
In patients undergoing H. pylori  eradication for the 
first time, one of the following four regimens can be used: 
14-day standard triple therapy, non-bismuth quadruple 
therapy, 7-day standard triple therapy after clarithromycin 
resistance test, and bismuth quadruple therapy.
(1) Standard triple therapy
Can standard triple therapy be one of the first-line ther-
apy for H. pylori eradication?
Statement 4. Standard triple therapy (standard dose 
PPI, amoxicillin 1 g, and clarithromycin 500 mg twice 
daily) for 14 days is recommended for first-line regi-
men.
Grade of recommendation: strong
Level of evidence: moderate
Experts’ opinions: completely agree (27.0%), mostly 
agree (50.0%), partially agree (14.0%), mostly disagree 
(9.0%), completely disagree (0%), not sure (0%)
To make appropriate choice of first-line regimen, we 
need to consider the regional resistance pattern and eradi-
cation rate. Many factors, such as compliance, gastric acid-
ity, and bacterial loads are related to the efficacy of triple 
therapy. However, the eradication rate of standard triple 
therapy is mainly influenced by clarithromycin resistance. 
Clarithromycin resistance has increased during the last 10 
years in Korea, and the resistance rate of clarithromycin in 
Korea is reported to be 17.8%–31.0%.2,14 The geographic 
distribution of clarithromycin resistance is highly variable. 
According to the recently published nationwide antibiotics 
resistance mapping study in Korea, the resistance rate of 
clarithromycin was less than 15% in the Seoul and Chun-
gcheong areas and over 15% in other parts of Korea.2 These 
Table 3. Indications for the Eradication of Helicobacter pylori 
Existing indication Added indication Admissive indication
Peptic ulcer disease After endoscopic resection of gastric adenoma Atrophic gastritis/intestinal metaplasia
Marginal zone B-cell lymphoma Iron deficiency anemia
After endoscopic resection of early gastric cancer
Family history of gastric cancer
Functional dyspepsia
Long-term low-dose aspirin user with a history of peptic ulcer
Idiopathic thrombocytopenic purpura
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results suggest that clarithromycin triple therapy is still ac-
ceptable as a first-line treatment in some parts of Korea.
To be eligible for a first-line treatment of H. pylori erad-
ication therapy, the regimen must show at least 80% to 85% 
of the eradication rate.8,64 To find an eradication rate for 
standard triple therapy in Korea, we searched and selected 
all RCTs conducted in Korea which have used clarithro-
mycin triple therapy since 2007. Twenty-six studies were 
included in meta-analysis (Supplementary Table 3).65-90 
Overall pooled eradication rates of standard triple therapy 
derived from these studies were 71.6% (95% CI, 69.9% to 
73.3%) in intention-to-treat (ITT) analysis and 79.6% (95% 
CI, 76.6% to 82.2%) in per protocol (PP) analysis (Fig. 
4). Studies were divided into 2007–2011 and 2012–2016. 
Pooled eradication rates of 2007–2011 and 2012–2016 
were 72.3% (95% CI, 71.2% to 74.4%) and 70.3% (95% CI, 
68.4% to 72.1%) in ITT analysis, respectively. The pooled 
eradication rate of standard triple therapy in 2012–2016 
was on the decline compared with 2007–2011. The pooled 
eradication rate of standard triple therapy was inadequate 
to be used as a first-line treatment. This result was similar 
to that of prospective RCT conducted in 2018 by Korean 
College of Helicobacter and Upper Gastrointestinal Re-
search.91 Therefore, to use the standard triple therapy as a 
first-line treatment, it is necessary to consider introducing 
a clarithromycin resistance test or extending the treatment 
duration.
Regarding duration of standard triple therapy, we ana-
lyzed the pooled eradication rate of 7-day, 10-day, and 14-
day therapy. The pooled eradication rate of 7-day standard 
triple therapy was 70.0% (95% CI, 68.5% to 71.4%) and 
that of 10-day therapy was 73.7% (95% CI, 69.8% to 77.2%) 
in ITT analysis. The pooled eradication rate (ITT) of 14-
day therapy was 78.1% (95% CI, 75.2% to 80.7%) which 
was significantly higher than those of 7-day and 10-day 
therapy (p<0.01 for both duration) (Supplementary Fig. 3). 
Eradication rates between the 7-day and 10-day therapy 
were not significantly different. A network meta-analysis 
published in 2017 that analyzed 34 RCTs since 2005 also 
showed similar results.92 The pooled eradication rates (ITT) 
of 7-day, 10-day, and 14-day standard triple therapy were 
71.1% (95% CI, 68.3% to 73.7%), 67.0% (95% CI, 60.0% to 
73.4%), and 76.4% (95% CI, 73.3% to 79.2%), respectively. 
In addition, according to a national multicenter study 
published in 2019, the eradication rates of 7-day standard 
triple therapy were 63.9% in ITT analysis and 71.4% in PP 
analysis.91 
Based on the above analysis and the available evidences, 
a 14-day therapy is recommended when considering stan-
dard triple therapy as a first-line treatment without clar-
ithromycin resistance test.
(2) Non-bismuth quadruple therapy
(a) Sequential therapy
Can sequential therapy be one of the first-line therapy 
of H. pylori eradication?
Statement 5. Sequential therapy (standard dose PPI, 
amoxicillin 1 g twice daily for 5 days followed by stan-
dard dose PPI, clarithromycin 500 mg, and metronida-
zole 500 mg twice daily for 5 days) can be one of first-
line therapies for H. pylori eradication.
Grade of recommendation: strong
Level of evidence: high
Experts’ opinions: completely agree (31.0%), mostly 
agree (39.0%), partially agree (9.0%), mostly disagree 
(21.0%), completely disagree (0%), not sure (0%)
In recent guidelines, non-bismuth quadruple therapy, 
sequential or concomitant treatment, or bismuth qua-
druple therapy is recommended as the first-line treatment 
in regions where clarithromycin resistance is more than 
15%.11,93 Non-bismuth quadruple therapy uses amoxicillin, 
clarithromycin, and metronidazole simultaneously with 
PPI, but each method has different duration of use for in-
dividual antibiotic. Sequential therapy is a method of using 
PPI and amoxicillin for the first 5 days, and then admin-
istering PPI, clarithromycin and metronidazole for 5 days 


























Fig. 4. Time trends of pooled Helicobacter pylori eradication rates of 
standard triple therapy from randomized controlled trials performed 
in Korea (by years). The overall eradication rates of standard triple 
therapy were 71.6% (95% confidence interval [CI], 69.9% to 73.3%) 
in ITT analysis and 79.6% (95% CI, 76.6% to 82.2%) in PP analysis. 
The eradication rates from 2007 to 2011 were 72.3% (95% CI, 71.2% 
to 74.4%) in ITT analysis and 81.5% (95% CI, 79.9% to 82.9%) in PP 
analysis. The eradication rates from 2012 to 2016 were 70.3% (95% CI, 
68.4% to 72.1%) in ITT analysis and 77.4% (95% CI, 75.6% to 79.2%) in 
PP analysis. 
ITT, intention-to-treat; PP, per protocol. *p<0.01.
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A meta-analysis of 24 RCTs (n=5,070) was conducted 
to confirm the effect on sequential therapy as the first-line 
treatment (Supplementary Table 4).75,77-80,90,94-111 Twenty 
RCTs compared comparing standard triple therapy, two 
RCTs comparing bismuth quadruple therapy, and two 
RCTs comparing hybrid therapy were included. RCTs 
comparing sequential therapy with concomitant therapy 
(CT) are described in the CT section.
i) Sequential therapy versus standard triple therapy 
Twenty studies compared the eradication rate between 
sequential therapy and conventional therapy. In all, 3,224 
and 3,152 patients were treated with sequential and stan-
dard triple therapies, respectively. The eradication rates 
of sequential therapy and overall standard triple therapy 
were 84.1% and 74.9% in the ITT analysis, respectively. 
The rates of sequential therapy and overall standard triple 
therapy were 85.9% and 77.3% in the PP analysis, respec-
tively. The pooled RR of the ITT eradication rates (sequen-
tial therapy vs standard triple therapy) was 1.37 with the 
fixed effects model (95% CI, 1.21 to 1.54) (Fig. 5), while 
the pooled RR of the PP eradication rates was 1.60 with the 
fixed effects model (95% CI, 1.40 to 1.83) (Supplementary 
Fig. 4).
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Fig. 5. Comparison between 10-day sequential therapy and standard triple therapy (TT) according to the treatment duration of TT in intention-to-
treat analysis. 
M-H, Mantel-Haenszel test; CI, confidence interval. *Risk of bias: A, random sequence generation (selection bias); B, allocation concealment 
(selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete 
outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias.
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ii) Sequential therapy versus bismuth quadruple therapy 
In the meta-analysis of two RCTs comparing 10-day 
sequential therapy with bismuth quadruple therapy, the 
eradication rates of the two therapies were not significantly 
different (RR, 0.79; 95% CI, 0.47 to 1.32 in ITT analysis; 
RR, 0.63; 95% CI, 0.27 to 1.49 in PP analysis). However, 
there was a limitation that the number of patients included 
was small and local studies were not included (Supplemen-
tary Fig. 5).
iii) Sequential therapy versus hybrid therapy 
In a meta-analysis of two RCT studies comparing 10-
day sequential therapy with hybrid therapy, the 10-day 
sequential therapy showed a lower eradication rate than 
hybrid therapy (RR, 0.36; 95% CI, 0.23 to 0.58 in ITT anal-
ysis; RR, 0.18; 95% CI, 0.10 to 0.35 in PP analysis) (Supple-
mentary Fig. 6). However, there was a limitation that the 
number of patients included was small and no local studies 
were included.
In summary, the eradication rate of 10-day sequential 
therapy as a first-line treatment was higher than that of 
standard triple therapy, and in the subgroup analysis, se-
quential therapy showed a higher eradication rate than 
the 7-day and 10-day standard triple therapy but a com-
parable eradication rate with the 14-day standard triple 
therapy. The comparative analysis of bismuth quadruple 
therapy and hybrid therapy was difficult to conclude due 
to the small number of RCTs. Therefore, as clarithromycin 
resistance increases in Korea, 10-day sequential therapy 
is recommended when first-line treatment is considered 
without clarithromycin resistance testing.
(b) Concomitant therapy
Can CT be one of the first-line therapy of H. pylori 
eradication?
Statement 6. CT (standard dose PPI, clarithromycin 
500 mg, amoxicillin 1 g, and metronidazole 500 mg 
twice daily for 10 days) is recommended as a first-line 
treatment. 
Grade of recommendation: strong
Level of evidence: high
Experts’ opinions: completely agree (66.7%), mostly 
agree (13.3%), partially agree (13.4%), mostly disagree 
(3.3%), completely disagree (3.3%), not sure (0%)
CT, in which amoxicillin, clarithromycin, and metro-
nidazole are administered simultaneously for 10 days is 
one of the non-bismuth quadruple therapy (concomitant, 
sequential, and hybrid therapy) used to overcome the 
decreased eradication rates of standard triple therapy. 
To investigate the efficacy of CT as first-line treatment 
of H. pylori eradication, we selected RCTs including CT. 
Short term treatment of CT (5-day CT or 7-day CT) were 
excluded. A total of 26 RCTs were finally eligible in this 
analysis and the characteristics of each study are shown in 
Supplementary Table 5.84,89,109,112-131 A total of 21 studies of 
10-day CT, six studies of 14-day CT and one RCT of both 
10-day CT and 14-day CT were included. The eradication 
rate for 10-day CT was 85% for ITT analysis and 91% for 
PP analysis, and the rate for 14-day CT was 86% for ITT 
analysis and 94% for PP analysis, which was higher than 
that of standard triple therapy. There was no difference in 
eradication rate according to the duration in the subgroup 
analysis. From the analysis including studies conducted in 
Korea only, the eradication rates of 10-day CT were 84% 
in ITT analysis and 92% in PP analysis, and those of 14-
day CT were 79% in ITT analysis and 94% in PP analysis; 
there was no difference in eradication rate according to the 
administration duration (Supplementary Table 6).
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Fig. 6. Comparison between 10-day concomitant therapy (CT) and 10-day/14-day standard triple therapy in intention-to-treat analysis.
ST, standard triple therapy; M-H, Mantel-Haenszel test; CI, confidence interval.
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compared to sequential therapy and a 17% higher eradi-
cation rate compared to 10-day/14-day standard triple 
therapy, and the evidence level was high. There was no 
difference in eradication rate between bismuth quadruple 
therapy and hybrid therapy, and the levels of evidence were 
evaluated as moderate and high, respectively.
Through the systematic search, 21 RCTs comparing 10-
day CT with other regimens were selected. Eight RCTs 
compared 10-day CT with 10-day/14-day standard triple 
therapy. The eradication rate of 10-day CT was signifi-
cantly higher than that of 10-day/14-day standard triple 
therapy (RR, 1.17; 95% CI, 1.05 to 1.30 in ITT analysis; RR, 
1.15; 95% CI, 1.06 to 1.25 in PP analysis) (Fig. 6).
In 13 RCTs, 10-day CT and 10-day sequential therapy 
were compared. The eradication rate of 10-day CT was 
significantly higher than that of the 10-day sequential 
therapy, but the difference seems to be small (RR, 1.04; 
95% CI, 1.00 to 1.08 in ITT analysis; RR, 1.04; 95%, CI 1.01 
to 1.07 in PP analysis) (Supplementary Fig. 7). The eradi-
cation rate of CT was slightly higher than that of sequential 
treatment, which is thought to be because CT is more ef-
fective than sequential treatment if it is resistant only to 
either clarithromycin or metronidazole. In fact, in case 
of clarithromycin resistance, CT had a higher eradication 
rate compared to sequential therapy.132,133 In the case of 
metronidazole-resistant but, not clarithromycin-resistant, 
CT also showed higher eradication rate than sequential 
therapy.132,134
In six RCTs, 10-day CT and 10-day/14-day of bismuth 
quadruple therapy were compared. The eradication rate 
of 10-day CT was not significantly different from that of 
bismuth quadruple therapy (RR, 1.05; 95% CI, 0.96 to 
1.15 in ITT analysis; RR, 1.01; 95% CI, 0.97 to 1.06 in PP 
analysis) (Supplementary Fig. 8). In two RCTs, 10-day CT 
and hybrid therapy were compared, and there was no dif-
ference between the two groups (RR, 0.99; 95% CI, 0.93 to 
1.05 in ITT analysis). The eradication rates of 14-day CT 
and 10-day/14-day sequential treatments were compared 
in three RCTs. The eradication rate of 14-day CT did not 
differ from that of 10-day/14-day sequential therapy in 
the ITT analysis (76% vs 79%), but in the PP analysis, the 
eradication rate of 14-day CT was slightly higher than that 
of sequential therapy (89% vs 82%). In two RCTs, 14-day 
CT and 14-day standard triple therapy were compared, 
and 14-day CT showed significantly higher eradication 
rate than 14-day standard triple therapy (88% vs 79% in 
ITT analysis; 94% vs 82% PP analysis). In two RCTs, 14-
day CT and hybrid therapy were compared, and 14-day CT 
showed slightly higher eradication rate than hybrid therapy 
(91% vs 85%, p=0.05 in ITT analysis; 96% vs 92%, p=0.07 
in PP analysis).
In summary, the eradication rate of 10-day CT as 
first-line treatment was significantly higher than that of 
10-day/14-day standard triple therapy but slightly higher 
than that of sequential therapy and similar to those of bis-
muth quadruple therapy and hybrid therapy. The eradica-
tion rate of 14-day CT was significantly higher compared 
to 14-day standard triple therapy in both PP and ITT 
analysis, and 10-day/14-day sequential therapy in the PP 
analysis. The eradication rates of 10-day CT and 14-day 
CT were similar. Therefore, if first-line treatment is consid-
ered without resistance test, 10-day CT is recommended.
(3) Standard triple therapy based on clarithromycin resis-
tance test
Does clarithromycin resistance test improve the eradi-
cation rate of standard triple therapy?
Statement 7. Clarithromycin resistance test by PCR 
or sequencing is recommended when a 7-day standard 
triple therapy is considered as a first-line treatment.
Grade of recommendation: strong
Level of evidence: low
Experts’ opinions: completely agree (76.7%), mostly 
agree (6.6%), partially agree (16.6%), mostly disagree 
(0%), completely disagree (0%), not sure (0%)
The eradication rate of empirical standard triple therapy 
(PPI + amoxicillin + clarithromycin) has been declined 
to about 70% through the last decades in Korea.135,136 The 
2013 revised Korean guideline recommended this therapy 
as one of primary regimens for H. pylori eradication, even 
though experts’ complete agreement rate of this strategy 
was only 53.6%.8 Maastricht V guideline recommended 
that clarithromycin-based triple therapy without suscepti-
bility testing should be abandoned when the regional clar-
ithromycin resistance rate is more than 15%.11 Considering 
the decreasing and sub-optimal eradication rate of this 
empirical therapy and high resistance rate of clarithromy-
cin in Korea, new strategies are desperate for improving 
eradication rate of H. pylori. 
Although clarithromycin susceptibility test by H. pylori 
culture is the best method for appropriate selection of H. 
pylori eradication regimens,137,138 it is very difficult to apply 
culture-based results to clinical practice because of slow 
growth of H. pylori and demanding culture conditions. On 
the contrary, tailored therapy after molecular testing using 
polymerase chain reaction (PCR)-kits or sequencing meth-
ods detecting 23S ribosomal RNA point mutations related 
to clarithromycin resistance is one of easily applicable 
methods. 
In the large case-control study (n=1,232), the patients 
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who had the A2142G and A2143G point mutations associ-
ated with clarithromycin resistance based on dual priming 
oligonucleotide-based multiplex PCR were treated with 
PPI + amoxicillin + metronidazole (PAM) for 7 days, and 
the patients without clarithromycin resistance were treated 
with standard triple therapy for 7 days (tailored therapy). 
The eradication rate of H. pylori in the tailored therapy 
group was 80.7% (176/218), which was significantly higher 
than that in the empirical 7-day standard triple therapy 
(69.5%, 214/308; p<0.01) or PAM (71.1%, 219/308; p=0.01) 
control groups in ITT analysis.82 In addition, the recent two 
case-control studies reported that 7-day tailored therapy 
with bismuth quadruple therapy, PAM, or standard triple 
therapy had higher eradication rates than those of empiri-
cal 7-day standard triple therapy (91.8% vs 72.1%; 94.3% 
vs 76.5%, respectively) in PP analysis.20,21 Importantly, the 
costs for a successful eradication with tailored therapy 
could be similar or superior to those of empirical 14-day 
standard triple therapy.21
(4) Bismuth quadruple therapy
Can bismuth quadruple therapy be one of the first-line 
therapy of H. pylori eradication?
Statement 8. Eradication rates of bismuth quadruple 
therapy (standard dose PPI twice daily, metronidazole 
500 mg three times daily, bismuth 120 mg and tetracy-
cline 500 mg four times daily for 10 to 14 days) are simi-
lar to 14 days standard triple therapy, 10 days CT, and 
10 days sequential therapy. However, because of its high 
adverse effects and potential use as second-line therapy, 
it can be recommended to be used as first-line therapy 
if other first-line therapy options are not available.
Grade of recommendation: weak
Level of evidence: moderate
Experts’ opinions: completely agree (50.0%), mostly 
agree (33.4%), partially agree (10.0%), mostly disagree 





























M-H, random, 95% CI
0.01 0.1 1 10 100
Risk ratio
M-H, random, 95% CI
10 14-day PBMT 14-day TT Risk ratio





























M-H, random, 95% CI
0.01 0.1 1 10 100
Risk ratio
M-H, random, 95% CI
10 14-day PBMT 10-day SQT Risk ratio



































M-H, random, 95% CI
0.01 0.1 1 10 100
Risk ratio
M-H, random, 95% CI
10 14-day PBMT 10-day CCT Risk ratio







Fig. 7. Comparison of the eradication rate of PBMT as first-line therapy in intention-to-treat analysis. (A) 10-day/14-day PBMT versus 14-day TT; (B) 
10-day/14-day PBMT versus 10-day SQT; and (C) 10-day/14-day PBMT versus 10-day CCT.
M-H, Mantel-Haenszel test; CI, confidence interval; PBMT, bismuth quadruple therapy; TT, standard triple therapy; SQT, sequential therapy; CCT, 
concomitant therapy. *Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of par-
ticipants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, 
selective reporting (reporting bias); G, other bias.
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Established guidelines recommended that bismuth qua-
druple or non-bismuth quadruple therapies are suitable 
for the first-line H. pylori eradication therapy in high clar-
ithromycin resistance areas.11,139 
In two network meta-analysis studies of the RCTs, the 
efficacy of bismuth-containing quadruple therapy varied 
depending on the type of eradication regimens and dura-
tion of therapies.140,141 We performed meta-analysis includ-
ing nine RCTs from January 2008 to July 2018 investigating 
the efficacy and safety of bismuth quadruple therapy for 
the first-line H. pylori eradication (Supplementary Table 7). 
Pooled eradication rates of bismuth quadruple therapy by 
ITT analysis and PP analysis were 84.5% (95% CI, 74.9% to 
90.9%) and 90.6% (95% CI, 82.8% to 95.1%), respectively. 
However, there was no statistically significant difference 
of ITT eradication rates in 10–14 days bismuth quadruple 
therapy compared to 14 days standard triple therapy (RR, 
1.28; 95% CI, 0.97 to 1.70) (Fig. 7A), 10 days sequential 
therapy (RR, 0.96; 95% CI, 0.83 to 1.12) (Fig. 7B), and 10 
days CT (RR, 1.01; 95% CI, 0.93 to 1.10) (Fig. 7C). In addi-
tion, there was no statistically significant difference of PP 
eradication rates in 10–14 days bismuth quadruple therapy 
compared to 14 days standard triple therapy (RR, 1.37; 
95% CI, 0.95 to 1.99), 10 days sequential therapy (RR, 0.99; 
95% CI, 0.93 to 1.05), and 10 days CT (RR, 1.01; 95% CI, 
0.95 to 1.07). Heterogeneity among studies was generally 
moderate, and we should interpret these results with cau-
tion due to small numbers of the current meta-analysis. 
In terms of adverse events, bismuth quadruple therapy 
was significantly higher than other eradication therapies 
(RR, 1.72; 95% CI, 1.23 to 2.40) (Supplementary Fig. 9). 
However, considerable heterogeneity was shown among 
studies (I2=92%). 
Bismuth quadruple therapy is regarded as a promising 
treatment for patients with allergy to penicillin as well as 
H. pylori with dual resistance.139 Therefore, it may be one 
of the attractive options for H. pylori eradication. Unfortu-
nately, there are few rescue therapies for H. pylori eradica-
tion, and high adverse events of bismuth quadruple ther-
apy cannot be ignored in clinical practice. Thus, bismuth 
quadruple therapy can be first-line treatment for H. pylori 
eradication when other first-line options are unavailable, 
due to its high adverse events rate and bismuth quadruple 
therapy is a widely used rescue therapy for other regimens. 
Further well-designed studies are required to confirm 
the efficacy of bismuth quadruple therapy for fist-line H. 
pylori eradication in Korea. Additionally, regarding the 
bismuth dosage, bismuth subcitrate (DeNolⓇ) 300 mg con-
tains elemental bismuth 120 mg. Therefore, physicians can 
prescribe bismuth subcitrate 300 mg four times daily in 
clinical practice. 
2) Salvage therapy
What is the recommended salvage regimen after failure 
of previous H. pylori eradication therapy?
In the last decade, the efficacy of PPI, clarithromycin, 
and amoxicillin triple therapy has decreased mainly due to 
clarithromycin resistance.142,143 As a result, it has become a 
common situation in clinical practice to choose a salvage 
regimen after failure of one or more eradication attempts. 
Moreover, the selection of a rescue regimen may be more 
complicated with the emergence of alternative first-line 
treatments such as sequential or concomitant therapies. 
In the systematic literature review, there were 36 RCTs 
that compared different combinations of antibiotics, dif-
ferent durations of a regimen, or different PPIs as salvage 
therapy after one or more eradication failures between 
2008 and 2017 (Supplementary Table 8):144-179 24 RCTs 
evaluated second-line regimens, five evaluated third-line 
regimens, five compared different durations of a regimen, 
and two compared different doses or kinds of PPIs. Most 
studies for second-line regimens were conducted after 
failure of clarithromycin-based triple therapy; there was 
no RCT that evaluated second-line regimens after failure 
of non-bismuth or bismuth quadruple therapy, and there 
was no RCT that evaluated third-line regimen after failure 
of first-line clarithromycin-based triple therapy followed 
by second-line bismuth quadruple therapy. Meta-analyses 
were conducted and there were more than three RCTs. The 
recommendations on the salvage regimen were primarily 
based on those RCTs and their meta-analyses. However, 
when no suitable trial was found, the most relevant cohort 
studies, published systematic reviews of cohort studies, and 
RCTs published before 2008 were referenced for the rec-
ommendations. All eradication rates presented below are 
from ITT analyses. The evidences which were included in 
the meta-analysis of regimens for salvage therapy are sum-
marized in the Supplementary Table 9.
Statement 9. After failure of standard triple therapy, a 
bismuths quadruple therapy (PPI, bismuth, tetracycline, 
and metronidazole) for 14 days is recommended as a 
second-line therapy.
Grade of recommendation: strong
Level of evidence: high
Experts’ opinions: completely agree (90.0%), mostly 
agree (6.7%), partially agree (3.3%), mostly disagree 
(0%), completely disagree (0%), not sure (0%)
In the 2013 revised Korean guidelines, bismuth qua-
druple therapy (PPI, bismuth, tetracycline, and metroni-
dazole) for 7–14 days was recommended. The systematic 
review conducted for the present guidelines identified 15 
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RCTs which compared 31 treatment arms as second-line 
treatment after failure of first-line PPI-clarithromycin-
amoxicillin triple therapy.144,149,153,158-160,162-165,171-173,176,179 
Of those, nine studies adopted bismuth quadruple 
therapy,153,158,159,162,164,172,173,176,179 and eight studies adopted 
levofloxacin triple therapy (PPI, amoxicillin, and levofloxa-
cin);144,149,162,163,165,172,173,179 of those, four studies compared 
bismuth quadruple therapy and levofloxacin triple therapy 
directly.162,172,173,179 
Bismuth quadruple therapy showed pooled eradica-
tion rate of 75.5% (95% CI, 71.6% to 79.1%) in the meta-
analysis of the nine studies (Fig. 8). Regarding the treat-
ment duration, four studies treated for 7 days, two for 10 
days, and three for 14 days. Because 10-day and 14-day 
regimens showed similar efficacy, subgroup analysis was 
conducted to compare 7-day versus 10- to 14-day bismuth 
quadruple therapy. In result, 10- to 14-day therapy showed 
significantly higher eradication rates (pooled eradica-
tion rate, 81.6%; 95% CI, 76.9% to 85.6%, I2=29.6%) than 
7-day therapy (pooled eradication rate, 68.4%; 95% CI, 
53.0 to 73.5%; I2=73.8%) (p<0.01). The systematic review 
also identified three RCTs comparing 14-day versus 7-day 
bismuth quadruple therapies. Meta-analysis of these RCTs 
also showed a significant eradication rate with 14-day regi-
men than 7-day regimen (risk difference [RD], 0.09; 95% 
CI, 0.02 to 0.15; p<0.01). 
Levofloxacin triple therapy showed pooled eradication 
rate of 73.1% (95% CI, 68.4% to 77.3%) in the meta-anal-
ysis of the eight studies (Fig. 9). In the subgroup analysis 
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Fig. 8. Meta-analysis of nine studies comparing bismuth quadruple therapy with other regimens after failure of first-line standard triple therapy. 
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Fig. 9. Meta-analysis of eight studies that compared levofloxacin triple therapy with other regimens after failure of first-line line clarithromycin triple 
therapy. The pooled eradication rate of levofloxacin triple therapy as a second-line therapy was 73.1% (95% confidence interval [CI], 68.4% to 77.3%).
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in four studies showed a significantly higher eradication 
rate (78.5%; 95% CI, 71.9% to 84.0%) than 7-day regimen 
in four studies (69.1%; 95% CI, 61.6% to 74.9%; p=0.04). 
One factorial RCT reported 10-day therapy showed sig-
nificantly higher eradication rate with 7-day therapy (87.5% 
vs 67.5%, p<0.01).174 Meanwhile, there was no significant 
difference in the dose of levofloxacin between 500 mg daily 
and 1,000 mg daily in this study (p=1.00). 
There was no significant difference in the eradica-
tion rates between bismuth quadruple therapy and levo-
floxacin triple therapy in the meta-analysis of four RCTs. 
There were non-significant contradictory trends favoring 
levofloxacin triple therapy in ITT analysis (bismuth qua-
druple vs levofloxacin triple: RD, –0.06; 95% CI, –0.14 
to 0.02; p=0.16) but favoring bismuth quadruple therapy 
in PP analysis (RD, 0.02; 95% CI, –0.05 to 0.10; p=0.58) 
(Supplementary Fig. 10). These results may be because 
of low tolerability of bismuth quadruple therapy. In two 
systematic reviews published in 2006, 10-day levofloxacin 
triple therapy showed superior efficacy compared to 7-day 
bismuth quadruple therapy.180,181 In our meta-analysis, two 
regimens were treated for the same duration (7 days vs 7 
days, 10 days vs 10 days, or 14 days vs 14 days). Thus, it 
can be suggested that bismuth quadruple therapy and levo-
floxacin triple therapy may have similar efficacy when the 
two treatments are administered for the same duration.
A major limitation of levofloxacin triple therapy is that 
efficacy of the regimen is substantially reduced in the pres-
ence of levofloxacin resistance.162 In Korea, the resistance 
rate for levofloxacin in H. pylori strains has been increas-
ing rapidly as high as 28.1%.14,182,183 Very recently, the na-
tionwide antibiotic resistance profile of H. pylori in Korean 
population was reported.2 According to this report, resis-
tance rate against levofloxacin was 37.0%. Thus, bismuth 
quadruple therapy would be favored over levofloxacin 
triple therapy in Korea. However, it should also be noted 
that resistance rate against metronidazole was also as high 
as 29.5% in the same study. Because resistance to metroni-
dazole can be overcome with increased duration and dose, 
14-day course would be preferred to 10- to 14-day course 
for bismuth quadruple therapy as a salvage regimen in 
Korea.184 Therefore, bismuth quadruple therapy for 14 days 
is recommended as a second-line therapy after failure of 
standard triple therapy.
Statement 10. After failure of non-bismuth quadruple 
therapy (sequential or concomitant therapy), a bismuth 
quadruple therapy is recommended as a second-line 
therapy.
Grade of recommendation: strong
Level of evidence: very low
Experts’ opinions: completely agree (60.0%), mostly 
agree (30.0%), partially agree (6.7%), mostly disagree 
(3.3%), completely disagree (0%), not sure (0%)
There was no RCT comparing salvage regimens after 
failure of first-line non-bismuth quadruple therapy. There 
was a meta-analysis of cohort studies in which most studies 
included were a levofloxacin triple regimen.185 In this study, 
the pooled eradication rate of levofloxacin triple therapy 
from five studies including 86 patients was 81% (95% CI, 
71% to 91%; I2=28%). Another meta-analysis conducted 
in Maastricht V guidelines showed 81% (six studies; 95% 
CI, 73% to 90%; I2=19%) after failure of sequential therapy 
and 78% (three studies; 95% CI, 58% to 97%; I2=67%) after 
failure of CT.11 However, these results may not be directly 
applicable to Korean population because of high levofloxa-
cin resistance rates as previously discussed.2,14,182,183
Bismuth quadruple therapy showed eradication rate of 
84% (95% CI, 63% to 106%; I2=56%) in the meta-analysis 
conducted in Maastricht V.11 However, the analysis in-
cluded only two cohort studies of similar sample sizes with 
each other. One of them was a study conducted in Korea 
where 14-day bismuth quadruple therapy achieved suc-
cessful eradication in 10 of 14 patients.
Therefore, bismuth quadruple therapy is recommended 
as a second-line therapy after failure of first-line non-
bismuth quadruple therapy based on currently available 
evidences. However, more data is required to support this 
recommendation.
Statement 11. After failure of bismuth quadruple 
therapy as first-line or second-line therapy (after failed 
standard triple or non-bismuth quadruple therapy), 
a levofloxacin triple therapy is suggested as a salvage 
therapy. 
Grade of recommendation: weak
Level of evidence: very low
Experts’ opinions: completely agree (40.0%), mostly 
agree (30.0%), partially agree (13.3%), mostly disagree 
(16.7%), completely disagree (0%), not sure (0%)
The most common situation in which bismuth quadru-
ple therapy fails in Korea is failures as a second-line regi-
men after failure of first-line standard triple therapy. This 
approach was recommended by previous Korean guide-
lines 2013 and Maastricht IV guidelines.8,186 The scenario 
in which second-line bismuth quadruple therapy fails after 
failure of first-line non-bismuth quadruple therapy is also 
expected to be a more common situation. In these cases, 
it is not recommended to use clarithromycin again in the 
third-line regimen.184 It would be also inappropriate to use 
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clarithromycin after failure of first-line bismuth quadruple 
therapy because this regimen had been chosen as first-line 
when clarithromycin resistance was suspected.8 Treatment 
regimen may be decided based on antibiotics susceptibility 
tests, either by culture, PCR, or sequencing analysis. Gen-
erally, it is recommended not to use clarithromycin, fluoro-
quinolone, and rifabutin again in the presence of resistance 
to respective drugs, while amoxicillin and metronidazole 
may be re-used.184 However, it is noteworthy that benefits 
of susceptibility-guided therapy over empirical regimen 
was evident only in the first-line treatment, not in the 
second-line setting in a recent systematic review.138 Neither 
was it in the third-line treatment in a recent RCT.187 The 
first-line and salvage treatment regimens and algorithms 
for H. pylori treatment combined with the regimens are 
summarized in Table 4 and Fig. 10, respectively. 
(1) Levofloxacin triple therapy
There was no RCT comparing rescue options after 
failure of bismuth quadruple therapy either as first-line 
or second-line regimen. In 2012, Gisbert reported on the 
efficacy of third-line PPI-amoxicillin-levofloxacin triple 
Table 4. Regimen of Recommended Therapies for Helicobacter pylori Infection
Regimen Drugs Frequency Duration (day)
Standard triple therapy PPI (standard dose)
Clarithromycin (500 mg)
Amoxicillin (1 g)
bid   7–14
Bismuth quadruple PPI (standard dose)



















Hybrid PPI (standard dose) + amoxicillin (1 g) then, PPI +  





Levofloxacin triple PPI (standard dose)
Levofloxacin (500 mg or 250 mg)
Amoxicillin (1 g)
bid
qd (500 mg), bid (250 mg)
bid
10–14
PPI, proton pump inhibitor; qd, once a day; bid, twice per day; tid, three times per day; qid, four times per day.
Fig. 10. Proposed algorithm for Helicobacter pylori treatment in Korea. Bismuth quadruple therapy as a first-line therapy is dotted because it is less 
preferred than other regimens. 




























Levofloxacin triple therapy (PPI-amoxicillin-levofloxacin) and others:
fluoroquinolone triple/quadruple, rifabutin containing therapy, high dose dual, concomitant therapy
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therapy in a systematic review of six cohort studies includ-
ing 350 patients and a cohort study including 200 of their 
own patients.188 This was updated in Maastricht V as 501 
patients in five studies resulting in pooled eradication rate 
of 70.0% (95% CI, 62.4% to 76.6%; I2=58.5%).11 A Korean 
study reported retrospective data from 14 medical centers 
in 2017, in which 110 patients received levofloxacin third-
line therapy, 88 adhered to the treatment protocol, and 63 
achieved successful eradication (62 after PPI-amoxicillin-
levofloxacin and one after PPI-amoxicillin-clarithromycin-
levofloxacin). The estimated eradication rate with third-
line levofloxacin triple therapy was 56.9% (62/109).189 
Although previously failed first- and second-line regimens 
were not specified in this study, this low eradication rate 
may have been due to the high levofloxacin resistance rate 
in Korea.2,14,182,183 Therefore, a levofloxacin triple therapy is 
suggested as a salvage therapy after failure of first-line or 
second-line bismuth quadruple therapy. However, the ef-
ficacy of this regimen may be lower than observed in the 
systematic review as indicated in the Korean retrospective 
study. 
(2) Triple therapy containing other fluoroquinolones
Three Japanese RCTs evaluated fluoroquinolone based 
triple therapy after first-line PPI-amoxicillin-clarithro-
mycin and second-line PPI-amoxicillin-metronidazole 
failure:147,157,178 the sitafloxacin-PPI-amoxicillin regimen 
showed an eradication rate of 70.0% (49/70; 95% CI, 59.0% 
to 81.0%) after 7-day therapy and 81.0% (51/63; 95% CI, 
71.0% to 90.9%) after 10-day therapy,147,157 while gatiflox-
acin-PPI-amoxicillin 7-day therapy was administered to 
only eight patients with six eradication successes (75%).178 
In European prospective cohort study, moxifloxacin-PPI-
amoxicillin 14-day therapy showed 82.4% eradication rate 
(206/250; 95% CI, 77.0% to 87.0%) after failure of first-line 
clarithromycin triple or non-bismuth quadruple therapy.190 
However, in a Korean retrospective cohort study, the same 
regimen with 7–14 days showed successful eradiation in 
only 67.9% (95% CI, 51.5-84.9%) after failure of first-line 
bismuth quadruple therapy.191 Thus, evidences are limited 
for triple therapy containing other fluoroquinolones after 
failure of bismuth quadruple therapy because the above-
mentioned studies are highly heterogeneous regarding the 
design and previous regimens. The potential cross-resis-
tance among fluoroquinolones may further limit the usage 
of other fluoroquinolones as alterative to levofloxacin in 
rescue therapy.183 
(3) Fluoroquinolone quadruple therapy
There was no RCT evaluating fluoroquinolone qua-
druple therapy after failure of bismuth quadruple therapy. 
However, eight RCTs compared 10 arms of various fluoro-
quinolone quadruple regimens with other regimens after 
failure of first-line triple therapy.144,148,149,154,159,160,166,168
The levofloxacin-bismuth quadruple regimen (levoflox-
acin, bismuth, PPI, and amoxicillin) was suggested as an 
“encouraging salvage strategy” in patients failing previous 
bismuth quadruple therapy in Maastricht V guidelines be-
cause of synergistic effects between bismuth and levofloxa-
cin to overcome antibiotics resistance.11 This regimen was 
evaluated in two RCTs with successful eradication rates 
of 84.8% (28/33; 95% CI, 72.6% to 97.1%) after 10-day 
therapy and 88.1% (126/143; 95% CI, 81.6% to 92.9%) after 
14-day therapy after failure of first-line PPI-amoxicillin-
clarithromycin/metronidazole.144,154 Two prospective co-
hort studies reported that levofloxacin-bismuth quadruple 
therapy showed 83.8% (31/37; 95% CI, 71.3% to 96.2%) 
eradication rate after failure of first-line clarithromycin tri-
ple and second-line bismuth quadruple therapy and 90.0% 
(180/200; 95% CI, 85.8% to 94.2%) after failure of first-line 
standard triple or non-bismuth quadruple therapy.192,193 
However, in an RCT reported from Hong Kong in 2007, 
levofloxacin-bismuth quadruple therapy achieved success-
ful eradication in 73% (37/51; 95% CI, 60.0% to 85.2%) 
subjects after ≥1 eradication failures, which was inferior to 
bismuth quadruple therapy.194 Therefore, although being 
expected to be effective, this regimen needs to be validated 
in Korean population before use.
The levofloxacin sequential regimen (levofloxacin, 
PPI, amoxicillin, and metronidazole followed by PPI and 
amoxicillin) also showed promising results in patients fail-
ing various first-line triple therapy, with successful eradi-
cation rates ranging between 82.2% and 90.2% in three 
RCTs.148,149,160 This regimen also needs verification for its 
efficacy after failure of bismuth quadruple therapy.
(4) Rifabutin containing regimen
The major limitations of using rifabutin for the eradica-
tion of H. pylori are high cost, myelotoxicity, and concerns 
for inducing resistance to Mycobacterium tuberculosis.195 
Three RCTs comparing rifabutin triple therapy (PPI-amox-
icillin-rifabutin) with other regimens as salvage treatment 
were reported before 2008.196-198 A systematic review re-
ported in 2012, which included those three RCTs, showed 
second-, third-, and forth-line eradication rates of rifabutin 
triple therapy were 79% (95% CI, 67% to 92%), 66% (95% 
CI, 55% to 77%), and 70% (95% CI, 60% to 79%), respec-
tively.195 It is recommended that rifabutin daily dose of 300 
mg and treatment duration of 10 days are appropriate for 
this regimen.139 There were another three RCTs including 
rifabutin containing regimens in the systematic review for 
the current guidelines.146,155,156 However, no study com-
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pared rifabutin triple therapy with other regimen after fail-
ure of bismuth quadruple therapy. They had highly hetero-
geneous designs among the studies with eradication rates 
ranging 77.8% to 96.3%. Therefore, rifabutin triple therapy 
may be suggested as one of rescue options after previous 
failure of multiple attempts including bismuth quadruple 
therapy. Nevertheless, relative lack of evidences and known 
risks should be carefully considered.
(5) High dose dual therapy
High dose dual therapy includes amoxicillin ≥3 g ad-
ministered ≥3 times daily to maintain high trough levels.139 
Only one RCT found in the systematic review, in which 
14-day rabeprazole 20 mg plus amoxicillin 750 mg four 
times daily achieved eradication rate of 89.3% (50/56; 95% 
CI, 80.9% to 97.6%) in patients with ≥1 eradication failures 
of unspecified regimens.151 Two RCTs conducted before 
2008 reported eradication rates of 70% (95% CI, 57.5% 
to 79.7%) and 75.6% (95% CI, 59.7% to 87.6%) as salvage 
therapy.197,199 This regimen may also be considered salvage 
therapy after failure of bismuth quadruple therapy, but 
more data is required to support this decision.
(6) Concomitant therapy
Although it is inappropriate to use clarithromycin again 
after failing clarithromycin containing regimen, CT (PPI-
amoxicillin-clarithromycin-metronidazole) may be select-
ed as a salvage treatment because combination of clarithro-
mycin and metronidazole may overcome clarithromycin 
resistance.184 However, there was no RCT which evaluated 
CT after failure of bismuth quadruple therapy in the sys-
tematic review. There was only one RCT which showed 
that 7-day CT achieved 86.5% (45/51; 95% CI, 76.9% to 
96.1%) after failure of first-line PPI-amoxicillin-clarithro-
mycin.171 One prospective cohort study nested in an RCT 
reported that 10-day CT showed 84.6% (11/13; 95% CI, 
57.8% to 95.7%) eradication rate after failure of first-line 
bismuth quadruple therapy.200
SUMMARY AND CONCLUSION
H. pylori is associated with socioeconomic burdens as 
it causes various gastrointestinal diseases and has a high 
prevalence rate of about 50% in Korea. It is clinically effec-
tive to establish therapeutic indications for H. pylori and 
to present effective primary and secondary treatment regi-
mens; this is important and necessary for the efficient use 
of national medical resources. In recent years, as the resis-
tance rate of H. pylori to clarithromycin has increased, the 
eradication rate of the existing standard triple therapy has 
tended to decrease. To overcome this, the treatment period 
has been extended or non-bismuth quadruple therapy such 
as sequential therapy or CT has been introduced. In the 
case of salvage therapy, it was difficult to select the right 
RCTs for each situation due to the diversity of first-line 
therapy regimens. As a result of meta-analyses of the latest 
RCTs published, bismuth quadruple therapy is recom-
mended after standard triple therapy, sequential therapy, or 
CT has failed. If bismuth quadruple therapy is used as the 
first-line or salvage therapy, levofloxacin triple therapy is 
recommended. However, its effectiveness may be reduced 
in areas with high resistance to levofloxacin, such as Korea. 
Although recommendations were made according to 
the resistance rate of Korea, implementing evidence-based 
medicine and using de novo meta-analysis, but it can also 
be applied in Far East Asia, which has a similar antibiotic 
resistance rate as Korea. In addition, recommendation 
on clarithromycin resistance testing based on PCR or se-
quencing have been made based on the latest literatures. 
We believe that the statement regarding tailored therapy 
will be useful for the use of resistance tests based on PCR 
or sequencing, which are widely used in clinical practice 
recently due to the convenience of use.
In this guideline, expert consensus was not reached on 
indications for eradication therapy for CAG/IM; therefore, 
further studies are needed to determine whether eradica-
tion therapy may lower the incidence of gastric cancer 
in CAG/IM. In addition, family history of gastric cancer 
is also a known risk factor of gastric cancer, and further 
research is needed to establish therapeutic indications for 
this. Studies on cost-effectiveness according to various 
combinations of first-line and salvage therapy regimens are 
also needed in future.
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